Overview

• Adjusted earnings per share reached $2.77, exceeding analysts’ $2.68 estimate.
• Second-quarter revenue hit $23.74 billion, surpassing the $22.84 billion consensus.
• The company halved its tariff cost outlook to $200 million from $400 million following a pause on U.S. levies for China imports.
• Darzalex sales climbed to $3.54 billion while the medtech unit’s operational revenue grew 6.1% to $8.54 billion.
• Management pledged $55 billion for U.S. manufacturing over four years and anticipates game-changing approvals across oncology, immunology and neuroscience.